12 completed, 4 recruiting, 1 terminated, 1 withdrawn. 12 Phase 1, 5 Phase 3, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 9, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 3 | 5 | Completed 3, Recruiting 2 |
| Phase 2 | 1 | Recruiting 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Taizhou Mabtech Pharmaceutical Co.,Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial Comparing the Efficacy and Safety of Anyouping® and Platinum-based Chemotherapy With or Without Enlituo® in Advanced Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Enlituo® + Anyouping® + PBC, Placebo-Enlituo + Anyouping® + PBC - Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | Phase 2 / Phase 3 | Recruiting | Taizhou Mabtech Pharmaceutical Co.,Ltd | 362 | 2026-09-16 | 2026-10-05 |
| Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status. Enlituo®, Erbitux® - Colorectal Cancer | Phase 3 | Recruiting | Taizhou Mabtech Pharmaceutical Co.,Ltd | 608 | 2026-05-27 | 2026-10-05 |
| Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy Volunteers Secukinumab 150mg s.c. - Psoriasis | Phase 1 | Completed | Taizhou Mabtech Pharmaceutical Co.,Ltd | 114 | 2025-12-15 | 2026-10-21 |
| Comparative Study of EnliTuo® Before and After Technology Change in Healthy Male Volunteers New technology Enlituo, Approved technology Enlituo - Healthy Adult Male | Phase 1 | Completed | Taizhou Mabtech Pharmaceutical Co.,Ltd | 86 | 2025-11-11 | 2026-09-30 |
| Safety and Tolerability of CMAB017 In Patients With Advanced Solid Tumors CMAB017 - Solid Malignancies | Phase 1 | Recruiting | Taizhou Mabtech Pharmaceutical Co.,Ltd | 55 | 2025-06-09 | 2026-10-21 |
| Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis CMAB015, Secukinumab - Psoriasis | Phase 3 | Completed | Taizhou Mabtech Pharmaceutical Co.,Ltd | 336 | 2024-08-27 | 2026-05-07 |
| To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria CMAB007, Xolair - Chronic Spontaneous Urticaria | Phase 3 | Completed | Taizhou Mabtech Pharmaceutical Co.,Ltd | 392 | 2024-06-18 | 2026-10-02 |
| Compare the PK, Safety, and Immunogenicity of Process-Changed CMAB007 and Xolair in Healthy Adult Male Subjects Process-Changed CMAB007, Xolair (omalizumab) - Healthy Volunteers (HV) | Phase 1 | Completed | Taizhou Mabtech Pharmaceutical Co.,Ltd | 114 | 2024-03-28 | 2025-11-24 |
| Study of CMAB807 Post-change in Manufacturing Site and Prolia in Healthy Volunteers Post-change CMAB807, Prolia - Healthy Volunteers | Phase 1 | Completed | Taizhou Mabtech Pharmaceutical Co.,Ltd | 128 | 2023-11-02 | 2024-11-07 |
| Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients Infliximab - Crohn Disease | Phase 4 | Recruiting | Taizhou Mabtech Pharmaceutical Co.,Ltd | 30 | 2023-09-21 | 2026-09-30 |
| Pharmacokinetic, Safety and Immunogenicity Study of CMAB015 and Cosentyx in Healthy Volunteers Secukinumab - Psoriasis | Phase 1 | Completed | Taizhou Mabtech Pharmaceutical Co.,Ltd | 130 | 2023-02-15 | 2024-04-10 |
| Study of CMAB807X Pre- and Post-change in Manufacturing Site and Xgeva® in Healthy Volunteers Post-change CMAB807X, Pre-change CMAB807X, Xgeva® - Healthy Volunteers | Phase 1 | Withdrawn | Taizhou Mabtech Pharmaceutical Co.,Ltd | 2023-02-01 | 2024-04-09 | |
| The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD, Safety and Immunogenicity CMAB007, Xolair - Healthy Volunteers | Phase 1 | Completed | Taizhou Mabtech Pharmaceutical Co.,Ltd | 114 | 2022-02-07 | 2023-06-12 |
| The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD and Safety Omalizumab - Asthma | Phase 1 | Completed | Taizhou Mabtech Pharmaceutical Co.,Ltd | 114 | 2020-12-01 | 2021-10-11 |
| Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC CMAB819, Nivolumab - Squamous Cell Carcinoma of the Head and Neck | Phase 1 | Terminated | Taizhou Mabtech Pharmaceutical Co.,Ltd | 21 | 2020-09-24 | 2024-04-09 |
| The Study of Infliximab (CMAB008 and Remicade) in Healthy Subjects to Compare the PK and Safety Infliximab - Rheumatoid Arthritis | Phase 1 | Completed | Taizhou Mabtech Pharmaceutical Co.,Ltd | 90 | 2020-02-01 | 2021-10-11 |
| Pharmacokinetic, Safety and Immunogenicity Study of CMAB809 and Herceptin in Healthy Volunteers CMAB809, Trastuzumab - Healthy Volunteers | Phase 1 | Completed | Taizhou Mabtech Pharmaceutical Co.,Ltd | 72 | 2019-06-17 | 2020-10-14 |
| CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer CMAB009, Irinotecan, Folinic acid - Metastatic Colorectal Cancer | Phase 3 | Completed | Taizhou Mabtech Pharmaceutical Co.,Ltd | 520 | 2017-12-12 | 2025-05-23 |
Psoriasis (3) · Colorectal Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Arthritis, Rheumatoid (1) · Asthma (1) · Chronic Urticaria (1) · Crohn Disease (1) · Neoplasm Metastasis (1) · Recurrence (1)
Omalizumab (4) · secukinumab (3) · Denosumab (2) · Infliximab (2) · CMAB009 (1) · Cetuximab (1) · Fluorouracil (1) · Irinotecan (1) · Leucovorin (1) · Nivolumab (1) · Trastuzumab (1)
China (18)
Hu Wei, Doctor (3) · Hui Tang, PhD (1) · Jia Jingying (1) · Jingying Jia, MSC (1) · Jingying Jia, Ph.D (1) · Jingying Jia, PhD (1) · Jinhua Xu, PhD (1) · Wu Jie (1) · Ye Guo, Ph.D (1) · Yi Ba Professor, Ph.D (1) · Yuankai Shi Professor, Ph.D (1)